Q-omics provides the consensus-scored CCT5P2 profile across patient tissues and cancer cell-line models. CCT5P2 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, CCT5P2 is differentially expressed in 10, with the highest sampling consensus in HNSC. Additionally, CCT5P2 RNA expression shows 8,076 significant gene co-expression associations, with the highest sampling consensus in ESCA. Together, these results highlight UVM, HNSC, and ESCA as cancer lineages where CCT5P2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CCT5P2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CCT5P2 survival associations across molecular data types. CCT5P2 RNA expression shows survival associations in the most cancer types (23). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CCT5P2 RNA expression–survival associations across cancer types. High CCT5P2 expression shows unfavorable associations in UVM, MESO and LIHC, but favorable associations in GBM, UCS and KIRP. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .005). Together, the overview and detailed table identify UVM as the clearest survival context for CCT5P2 RNA expression.
This table summarizes CCT5P2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for CCT5P2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CCT5P2 shows higher tumor expression in HNSC, COAD, UCEC, STAD, LUAD and LIHC. The HNSC box plot shows higher CCT5P2 RNA expression in tumor versus normal tissue (log2 FC = +0.087, t-test p < 0.001).
This table shows molecular features associated with CCT5P2 in patient tissues and cancer cell lines. In patient samples, CCT5P2 shows the broadest associations at the RNA and protein expression levels, with ESCA recurring as the lineage with the largest associated feature set.
